Page 299 - Read Online

Harrod et al. Hepatoma Res 2019;5:28 I http://dx.doi.org/10.20517/2394-5079.2019.15 Page 10 of 13

3. Kobayashi M, Ikeda K, Hosaka T, Sezaki H, Someya T, et al. Natural history of compensated cirrhosis in the Child-Pugh class A
compared between 490 patients with hepatitis C and 167 with B virus infections. J Med Virol 2006;78:459-65.
4. Toshikuni N, Izumi A, Nishino K, Inada N, Sakanoue R, et al. Comparison of outcomes between patients with alcoholic cirrhosis and
those with hepatitis C virus-related cirrhosis. J Gastroenterol Hepatol 2009;24:1276-83.
5. Wirth TC, Manns MP. The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma. Ann Oncol 2016;27:1467-74.
6. Gaddikeri S, McNeeley MF, Wang CL, Bhargava P, Dighe MK, et al. Hepatocellular Carcinoma in the Noncirrhotic Liver. Am J
Roentgenol 2014;203:34-47.
7. El-Refaie A, Savage K, Bhattacharya S, Khakoo S, Harrison TJ, et al. HCV-associated hepatocellular carcinoma without cirrhosis. J
Hepatol 1996;24:277-85.
8. Yeh M, Daniel H, Torbenson M. Hepatitis c associated hepatocellular carcinomas in non- cirrhotic livers. Mod Pathol 2010;23:276-83.
9. Ray RB, Meyer K, Ray R. Hepatitic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully
treated early hepatocellular carcinoma. Virology 2000;271:197-204.
10. Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006;25:3834-47.
11. McCombs J, Matsuda T, Tonnu-Mihara I, Saab S, Hines P, et al. The risk of long-term morbidity and mortality in patients with
chronic hepatitis c : results from an analysis of data from a department of veterans affairs clinical registry. JAMA Intern Med
2014;174:204-12.
12. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, et al. Association between sustained virological response and all cause
mortality among patients with chronic hepatitis c and advanced hepatic fibrosis. J Am Med Assoc 2012;308:2584-93.
13. Cabibbo G, Petta S, Barbara M, Attardo S, Bucci L, et al. Hepatic decompensation is the major driver of death in hcv-infected cirrhotic
patients with successfully treated early hepatocellular carcinoma. J Hepatol 2017;67:65-71.
14. Heim MH. Innate immunity and HCV. J Hepatol 2013;58:564-74.
15. McHutchison JG. et al. Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C. N
Engl J Med 1998;339:1485-92.
16. Manns M P, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006;55:1350-9.
17. Hsu CS, Chao YC, Lin HH, Chen DS, Kao JH. Systematic review: impact of interferon-based therapy on hcv-related hepatocellular
carcinoma. Sci Rep 2015;5:1-9.
18. Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. J Am Med Assoc 2014;312:631-40.
19. Geddawy A, Ibrahim YF, Elbahie NM, Ibrahim MA. Direct acting anti-hepatitis C virus drugs: Clinical pharmacology and future
direction. J Transl Intern Med 2017;5:8-17.
20. Putra J, Schiano T, Fiel MI. Histological assessment of the liver explant in transplanted hcv-patients achieving sustained virologic
response with direct-acting antiviral agents. Histopathology 2018;72:990-6.
21. Ahmad J, Eng F, Branch AD. HCV and HCC : clinical update and a review of hcc-associated viral mutations in the core gene. Semin.
Liver Dis 2011;31:347-55.
22. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, et al. Incidence of hepatocellular carcinoma and associated risk factors
in hepatitis c-related advanced liver disease. Gastroenterology 2009;136:138-48.
23. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HYt, et al. Maintenance peginterferon therapy and other factors associated
with hepatocellular carcinoma in patients with advanced hepatitis c. Gastroenterology 2011;140:840-9.
24. Shiffman ML, Morishima C, Dienstag JL, Lindsay KL, Hoefs JC, et al. Effect of HCV RNA suppression during peginterferon alfa-2a
maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology 2009;137:1986-94.
25. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, et al. Outcome of sustained virological responders with histologically
advanced chronic hepatitis c. Hepatology 2010;52:833-44.
26. Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, et al. Impact of peginterferon and ribavirin therapy on
hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010;52:652-7.
27. Kusano H, Akiba J, Ogasawara S, Sanada S, Yasumoto M, et al. Pegylated interferon-α2a inhibits proliferation of human liver cancer
cells in vitro and in vivo. PLoS One 2013;8:1-10.
28. Llovet JM, Fuster J, Bruix J. The barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transplant
2004;10:115-20.
29. Zhang YJ, Liu YT, Yu XS. Effect of interferon therapy on outcomes after hepatic resection for hepatitis C virus-related hepatocellular
carcinoma: a meta-analysis. Int J Clin Exp Med 2016;9:1675-83.
30. Tanimoto Y, Tashiro H, Aikata H, Amano H, Oshita A, et al. Impact of pegylated interferon therapy on outcomes of patients with
hepatitis c virus-related hepatocellular carcinoma after curative hepatic resection. Ann Surg Oncol 2012;19:418-25.
31. Singal AK, Freeman DH Jr, Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular
carcinoma. Aliment Pharmacol Ther 2010;32:851-8.
32. Miao RY, Zhao HT, Yang HY, Mao YL, Lu X, et al. Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related
hepatocellular carcinoma: a meta-analysis. World J. Gastroenterol 2010;16:2931-42.
33. Kushner T, Dieterich D, Saberi B. Direct-acting antiviral treatment for patients with hepatocellular carcinoma. Curr Opin
Gastroenterol 2018;34:1-8.
34. Prenner SB, Kulik L. Hepatocellular carcinoma in the wait-listed patient with hepatitis C virus. Curr Opin Organ Transplant
2018;23:237-43.
35. Saberi B, Dadabhai AS, Durand CM, Philosophe B, Cameron AM, et al. Challenges in treatment of hepatitis c among patients with